Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Newborn screening bill

This article was originally published in The Gray Sheet

Executive Summary

The Newborn Screening Saves Lives Act passes out of the Senate Health, Education, Labor and Pensions Committee Nov. 14. Introduced by Christopher Dodd, D-Conn., S. 1858 was unanimously accepted with a clarifying amendment. It would, among other provisions, authorize $15 million for states to expand their newborn screening programs and seek federal guidelines to test for all 29 disorders recommended for testing by the American College of Medical Genetics. The act would also create a research program to identify and develop new screening technologies

You may also be interested in...



Newborn genetic screening bill signed into law

A newborn genetic screening bill signed into law by President Bush April 24, the Newborn Screening Saves Lives Act of 2007, authorizes $15 million in grants for states to expand their newborn screening programs and calls for national guidelines on what conditions should be tested. The act, which was introduced by Sen. Christopher Dodd, D-Conn., also creates a research program to identify and develop new screening technologies ("1The Gray Sheet" Nov. 19, 2007, In Brief)

Good News For Immunomedics' Triple Negative Breast Cancer Trial

A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.

Takeda, CSL, Other Blood Plasma Firms Team On Hyperimmune COVID-19 Therapy

Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.

UsernamePublicRestriction

Register

MT025501

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel